Late incidence and recurrence of new-onset atrial fibrillation after isolated surgical aortic valve replacement




Björn Rikhard, Nissinen Maunu, Lehto Joonas, Malmberg Markus, Yannopoulos Fredrik, Airaksinen KE Juhani, Hartikainen Juha EK, Nieminen Tuomo, Biancari Fausto, Gunn Jarmo, Kiviniemi Tuomas O

PublisherElsevier Inc.

2022

Journal of Thoracic and Cardiovascular Surgery

The Journal of thoracic and cardiovascular surgery

J Thorac Cardiovasc Surg

164

6

1833

1843

0022-5223

1097-685X

DOIhttps://doi.org/10.1016/j.jtcvs.2021.03.101

https://www.sciencedirect.com/science/article/pii/S0022522321005870?via%3Dihub

https://research.utu.fi/converis/portal/Publication/56328808



Atrial fibrillation (AF) is a common complication after cardiac surgery. More knowledge is needed about long-term AF recurrence and adverse outcomes related to new-onset AF (NOAF) during the index hospitalization.

A total of 1073 patients underwent isolated surgical aortic valve replacement at the 4 participating hospitals (2002-2014). After the exclusion of patients with a history of any preoperative AF, the final study population included 529 patients in the bioprosthetic and 253 patients in the mechanical valve prosthesis cohort. Median follow-up time was 5.4 (interquartile range, 3.4-8.2) years in the combined cohort.

Altogether 333 (42.6%) patients had in-hospital NOAF and 250 (32.0%) AF after hospital discharge. In the mechanical cohort, 64 (25.3%) experienced in-hospital NOAF and 74 (29.2%) AF after hospital discharge, whereas in the bioprosthetic cohort, 269 (50.9%) patients had in-hospital NOAF and 176 (33.3%) AF after hospital discharge. Patients with NOAF during the index hospital stay had a multifold risk of AF after hospital discharge in the combined cohort (hazard ratio [HR], 3.68; 95% confidence interval [CI], 2.82-4.81; P < .0001) as well as in both cohorts separately (bioprosthetic: HR, 4.35; 95% CI, 3.05-6.22; P < .001; mechanical: HR, 2.54; 95% CI, 1.59-4.03; P < .001). Patients with an in-hospital NOAF also had a significantly higher adjusted risk of death during the follow-up in the mechanical (HR, 2.05; 95% CI, 1.10-3.82; P = .025) and bioprosthetic (HR, 1.63; 95% CI, 1.17-2.28; P = .004) valve prosthesis cohorts.

NOAF during the index hospitalization is associated with a 2- to 4-fold risk of later AF and 1.6- to 2.0-fold risk of all-cause mortality after mechanical and bioprosthetic surgical aortic valve replacement.


Last updated on 2024-26-11 at 18:52